Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sovateltide - Midwestern University/Pharmazz

Drug Profile

Sovateltide - Midwestern University/Pharmazz

Alternative Names: IRL-1620; PMZ-1620; Sovatelitide; SPI-1620

Latest Information Update: 30 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Pharmazz; Spectrum Pharmaceuticals
  • Class Antidementias; Antineoplastics; Imaging agents; Neuroprotectants; Peptides; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Angiogenesis modulating agents; Antioxidants; Apoptosis inhibitors; Diagnostic imaging enhancers; Endothelin B receptor agonists; Neurogenesis stimulants; Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Solid tumours; Stroke
  • Phase II Alzheimer's disease; Spinal cord injuries
  • Preclinical Brain hypoxia-ischaemia
  • No development reported Cerebrovascular disorders; Neurodegenerative disorders
  • Discontinued Biliary cancer; Non-small cell lung cancer

Most Recent Events

  • 30 May 2022 Pharmazz announces intention to submit marketing authorisation application to the Central Drugs Standard Control Organization (CDSCO) for Stroke in India
  • 25 May 2022 Interim effiacay and adverse events data from a phase III trial in Stroke released by Pharmazz
  • 17 Feb 2022 Pharmazz completes enrolment in phase III trial in Stroke in India (NCT04047563)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top